ArticleThe Laryngoscope2026
Predicting Different Recurrence Risk in HNSCC Using Circulating Inflammatory and T-Cell Biomarkers.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHead and neck squamous cell carcinoma (HNSCC) lacks reliable prognostic circulating biomarkers, and the role of the immune system in its progression remains incompletely understood. This study aimed to evaluate the prognostic value of systemic inflammatory and immune biomarkers in surgically treated patients with primary oral cavity (OCSCC) or laryngeal squamous cell carcinoma (LSCC).
methodsThis retrospective single-center study included 394 patients with OCSCC or LSCC who underwent surgery with curative intent. Preoperative blood samples were analyzed to assess platelet, neutrophil, lymphocyte, and monocyte counts, as well as T-cell subpopulations (CD3+, CD4+, and CD8+). Composite ratios-including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and systemic immune-inflammation index (SII)-were evaluated for their correlation with global (GR), local (LR), and distant (DR) recurrence risk.
resultsUnivariate analysis identified elevated platelet counts, PLR, SII, and neutrophil levels as significantly associated with increased GR (p = 0.0001, p = 0.0014, p = 0.0058 and p = 0.016, respectively) and LR risk, with the exception of neutrophil levels (p = 0.0002, p = 0.0008, p = 0.0072, respectively). In contrast, higher CD4+/CD3+ (p = 0.038) and CD4+/CD8+ (p = 0.045) ratios were associated with reduced DR risk. Multivariate analysis confirmed platelet count as an independent predictor for GR (p = 0.0001) and LR (p = 0.0002), while a high CD4+/CD8+ ratio (p = 0.045) was independently protective against DR.
conclusionThese findings highlight the prognostic relevance of platelet-related inflammatory markers and circulating T-cell ratios in recurrence risk among HNSCC patients. The differential associations with local versus distant recurrence underscore the complex interplay between systemic inflammation and adaptive immunity. Prospective validation is warranted to confirm these biomarkers' utility. LEVEL OF EVIDENCE: 4:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.